MSH2 and cancer: Unlike sporadic MSI cancer, Lynch-like patients are nearly impossible to differentiate from Lynch patients; they are MSI-positive and cancer tissues express abnormal MMR protein, not only for MLH1 as in sporadic MSI cancers but also for the other MMR proteins, such as MSH2, MSH6, and PMS2, as in Lynch syndrome cancers.